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ABSTRACT 
Ovarian cancer is one of the most common gynaecological cancers today.  Due to the high 
relapse rates (75%) in advanced ovarian cancer cases and the increasing resistance to currently 
available treatments, research into the development of new therapies is therefore required. This 
study therefore aims to evaluate the anticancer effects of Ficus exasperata extracts and 
fractions on ovarian cancer cells and to identify some of the active components. 
The antiproliferative activity of the crude extracts (1 mg/mL) was assessed using the 
MTT assay on A2780 (ovarian cancer) cell line. Fractionation of the chemical constituents by 
flash chromatographic technique was guided by the antiproliferative activity. Identification 
was further achieved using high resolution mass spectrometry and nuclear magnetic resonance 
spectroscopy. Observation of the dead cells was carried out via microscopy.  
All crude extracts tested exhibited antiproliferative activity except for the first phase of 
the methanol extract (MFF1) which interestingly showed proliferative effects. Five fatty acids 
were identified from the active fractions (FB1-10 and FB1-12). FB1-12 exhibited an IC50 value 
RIȝJP/7KHOHDVWSRWHQWIUDFWLRQ)%-4+5) had an IC50 YDOXHRIȝJP/%RWK
H1-HEX and H1-MET displayed inhibitory effects (97.2% and 97.9% respectively) compared 
to control.   
It can therefore be concluded that Ficus exasperata extracts exhibit significant 
antiproliferative and cytotoxic effects on ovarian cancer cells.  
 
Keywords: Ficus exasperata; ovarian cancer; MTT assay; A2780 cells; Flash 
chromatography; Fatty acids; Hexane; Ethylacetate; Methanol; NMR 
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1. Introduction 
Ovarian cancer (OC) is an overarching term for malignancies originating from different cell 
types within the ovaries.  It has become one of the great challenges faced by clinicians in 
gynaecologic oncology [1]. It currently stands as the eighth most common cancer in women 
and the seventh most common cause of cancer death [2]. Many theories attempt to explain the 
SDWKRORJLFDO SURFHVVHV LQYROYHG LQ 2& HDFK KDV LWV¶ OLPLWDWLRQV DQG QR VLQJOH WKHRU\ FDQ
completely explain all aspects of the disease process.  Persistent ovulation is a possible cause 
due to repeated trauma, repair and remodelling of the tissues within the ovaries [3].  This may 
increase the risk of mutational changes upon repair.  Another theory proposes opposing effects 
of androgens and progestogens; androgens resulting in increased tumour formation and 
progestogens exerting a protective effect [3].  Genetic mutations have also been observed to 
exist in a small proportion of individuals who develop OC [1].  A lack of disease-specific 
symptoms can make OC diagnosis difficult (symptoms may be confused with conditions such 
as endometriosis and menstruation) and so a large proportion of diagnoses are made at 
advanced stages (around 62%) [4] complicating therapy.  It has also been estimated that only 
15% of cancers remain localised to the ovary at the time of diagnosis; this further complicates 
treatment  [4].  
Despite improvements in OC treatment over the past decades, it is obvious that further 
research is needed in order to improve mortality and survival rates.  This is evidenced in the 
fact that 75% of patients with advanced OC, relapse after initial treatment [5].  Current 
treatments may well induce remission; however, relapse rates indicate that these treatments are 
not as effective as intended.  Research should focus on both novel therapies and optimisation 
of current therapies [5].  Increasing need for new drug therapies and treatments for OC has 
resulted in increases in natural products research.  For instance, the anticancer effects of green 
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teD DQG LWV¶ FRPSRQHQWV KDYH indicated promising results in vitro [6]. Traditional Chinese 
medicine also holds good promise for new anticancer drug development leads [7].  
The Ficus species are an emerging group of plants with promising potent anticancer 
constituents. F. carica, F. religiosa and F. septica have been widely studied [8±10].  Positive 
cytotoxicity results with these Ficus species suggest that Ficus exasperata (FE) could be 
another potential area for the development of novel anticancer agents.  Previous research on 
FE has been centred around effects on gynaecological structures and toxicity [11,12].  Today, 
there are currently unmet clinical needs with regards to the treatment of OC.  This study is 
therefore aimed at the identification of potential anticancer activities of a variety of extracts 
from FE in an OC cell line (A2780) and the identification of the compounds from these active 
extracts. To our knowledge, this is the first report on the antiproliferative effect of FE on 
ovarian cancer cell lines. 
 
2. Materials and methods 
2.1 Plant Material Extraction 
The leaves, figs and stem bark of FE were collected in September, 2010 from Benin City, 
Nigeria. The plant was previously authenticated by Mr. Felix Usang of the Forest Research 
Institute of Nigeria (FRIN), Ibadan, with a voucher number of F.H.I. 107312. Voucher 
specimen were prepared and deposited at FRIN and at the Department of Pharmacognosy, 
University of Benin, Nigeria. The fresh plant materials were cleaned, dried and powdered.  The 
figs (79 g), stem bark (450 g) and leaves (500 g) were macerated and constantly stirred in 
acetone, ethyl acetate (EtOAc), methanol and hexane, each for 72 h.  Following maceration, 
each extract was filtered and concentrated under a vacuum.  Extracts were weighed and stored 
at -20°C until required.  Extraction of figs produced three extracts: the acetone fig extract 
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(AFF1) (10.5 mg), the ethyl acetate Ficus fig extract (EFF1) (20.5 mg) and the methanol Ficus 
fig extract (MFF1) (23.1 mg);  Extraction of the stem bark produced three major extracts: the 
Ficus exasperata hexane bark extract (FEBH) (98 mg), the Ficus exasperata ethyl acetate bark 
extract (FEBE) (86 mg) and the Ficus exasperata methanol bark extract (FEBM) (70 mg). 
Extraction of the leaves with hexane (using a Soxhlet extractor set at 40°C) produced the 
hexane extract (H1) (19.23 g). All solvents used were obtained from Fisher Scientific, UK 
(HPLC grade unless otherwise stated).   
2.2 In Vitro Anticancer Assay of Crude Extracts 
2.2.1 Cell Line Culture 
A2780 human ovarian carcinoma cell lines (originally purchased from Sigma Aldrich, UK) 
were cultured in 75 cm2 Corning flasks (Corning Inc, NY) prior to assay.  Cells were cultured 
in media (RPMI 1604 supplemented with 10% Foetal Bovine Serum (PAA Laboratories, 
Austria) and 1% concentrations of Penicillin, Streptomycin, Glutamine and Sodium Pyruvate 
(all Sigma Aldrich, UK)).  Incubation conditions of 37 °C and 5% CO2 were maintained 
throughout.  Media was removed and cells washed with 5 mL of Hanks Balanced Salt Solution 
(Life Technologies, UK) twice.  Two minutes incubation with Trypsin (5 mL) was allowed for 
removal of adherent cells from the flask walls.  Centrifugation at 1000 rpm for 2 min produced 
a pellet of cells and a supernatant (removed).  After addition of 10 mL of media, cells were 
counted using a counting slide and microscope (Nikon TMS microscope fitted with Moticam 
(800 x 600 pixels)) to determine the cell solution volume to be added to each well to yield 
20,000 cells/well.  Cell distribution was examined under the microscope and then allowed to 
attach and recover within a 24 h incubation period.  
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2.2.2 Sample Preparation and MTT Antiproliferative Assay 
Stock solutions of 20 mg/ml were prepared using approximately 100 mg of extract in an 
appropriate volume of dimethylsulphoxide (DMSO).  The extract stock solutions were diluted 
to produce a final concentration of 1 mg/ml which were added to the respective wells of the 
96-well plate.  Quadruplicates were used in all assays.  Control, blank, and vehicle controls 
(100% DMSO and 1% DMSO) were also plated (minimum of 4 wells each).  After inoculation, 
the plate was incubated for 24 h. The yellow tetrazolium salt 3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide (MTT) antiproliferative assay was performed after incubation. 
The principle applied involves the ability of metabolically active cells being able to convert the 
dye to water-insoluble dark blue formazan and in the process reducing cleavage of the 
tetrazolium ring [13].  MTT was dissolved in Phosphate Buffer Solution to produce a 5 mg/mL 
VROXWLRQLWZDVWKHQILOWHUHGXVLQJ0LOOH[6\ULQJH'ULYHQ)LOWHU8QLWȝPEHIRUHEHLQJ
combined with media to produce 10 mL MTT-media solution (20% MTT : 80% media).  Media 
and extracts were aspirated IURPWKHZHOOSODWHSULRUWRDGGLWLRQRIȝ/ZHOORI077-
media solution.  Cells were checked under the microscope and then incubated for 4 h. After 
incubation, the MTT-media solution was removed and 150 ȝ/ZHOO '062 ZDV DGGHG WR
solubilise the formazan products formed.  After 5 min incubation with 100% DMSO, the 
optical density of the plate was read using an ELISA reader and Softmax Pro software.  The 
optimum wavelength was read with respect to the reference wavelengths (550 nm and 650 nm 
respectively). Results were converted to % cell inhibition due to extract presence compared to 
control (% inhibition = ((1-(Average AUsample/Average AUcontrol)) x 100).  
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2.3 Chromatographic Analysis of Active Extracts 
The active extracts selected from the cytotoxicity analysis which included all extracts except 
MFF1, were analysed on Thin Layer Chromatography (TLC) plates (Silica Gel 60 F254, Merck, 
Germany).  A 5 cm run was used with a hexane:EtOAc solvent system (plate one 70:30 and 
plate two 90:10).  Samples were dissolved in a small amount of EtOAc.  Bergapten, (previously 
identified from the stem EtOAc extract) was also spotted for comparative purposes.  Plates 
were subsequently visualised under both short and long wave UV light and retention factor 
(Rf) values calculated (Rf = spot height/solvent front height). 
After fractionation (described below), H1, H1-HEX and H1-MET were analysed on 
TLC plates produced as previously described.  Solvent systems were as follows: plate one 
EtOAc:methanol (90:10), plate two hexane:EtOAc (90:10) and plate three hexane:methanol 
(95:5).  Different solvent systems were utilised in order to allow for future use of the system 
which yielded the best Rf value.  Plates were visualised as previously described.  FB1 fractions 
were analysed on TLC plates using the hexane:EtOAc (90:10) solvent system. 
 
2.4 Purification and Fractionation of Active Extracts 
H1, and FEBE were found to be most active from bioassay results.  FEBE was further 
shortened to FB1.  Further fractionation and separation procedures were then performed. 
Liquid/liquid partitioning of H1 was carried out using hexane and aqueous methanol 
((AM) 10% water and 90% methanol) in a separatory funnel.  The AM phase was collected 
(after shaking and settling) into a conical flask and then replaced.  This was repeated three 
times and both phases were collected and filtered.  After filtration, the AM and hexane phases 
were concentrated using a Rotavapor R3, set at a temperature of 40°C.  These were labelled 
H1-MET and H1-HEX and assayed, as previously described, at a concentration of ȝJPl.   
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FB1 was prepared for dry loading flash chromatography by combining 1 g FB1 
dissolved in 1.8 ml EtOAc with 1 g Celite ® (Sigma Aldrich, UK).  A step-wise gradient system 
utilizing two solvent-system combinations (hexane and EtOAc) in each run was performed for 
FB1 elution using a flash chromatogram. The mixture was dried overnight and loaded into a 
12 g column and run using a flash chromatogram set at flow rate of 10 mL/min, run length 90 
min, ELSD threshold 5 mV, UV threshold 0.05AU, UV1 245 nm, UV2 280 nm and per-vial 
volume 5 mL.  The step gradient elution was as follows: step 1: hexane (A)-EtOAc (B) (100% 
A -0% B changing to 90% A- 10% B in 45 min). Step 2: (90% A -5% B changing to 70% A- 
30% B in 45 min). Fractions were collected in volumes of 50 mL. About 500 fractions were 
collected and subsequently pooled by TLC (a 4 cm run was used with 0.5 cm spot spacing and 
a 90:10 hexane:EtOAc solvent system).  Every second fraction was tested.  Fractions were 
pooled based on similarities under UV light.  A total of 17 fractions were obtained (FB1-1 to 
FB1-18, with FB1-4 and FB1-5 combined due to similarities in the NMR spectra).  All 
fractions were tested using the MTT antiproliferative assay, as described above, using a 1 
mg/mL stock solution.  FBC range 1-100 ȝJP/ZDVXVHGWRSURGXFHFRQFHQWUDWLon-inhibition 
profiles and compute IC50 and log IC50 values. 
 
2.5 1H-NMR and MS Analysis of Extracts and Fractions 
Extracts were prepared for Nuclear Magnetic Resonance (NMR) spectroscopy and Mass 
Spectrometry (MS) analysis.  Approximately 5-10 PJRIHDFKH[WUDFWZDVGLVVROYHGLQȝl 
of deuterated chloroform (CDCl3) (Sigma Aldrich, UK).  H1-HEX, H1-MET and FB1 
fractions were constituted in CDCl3 (ȝl) for 1H-NMR analysis.  An AS-400 JEOL NMR 
instrument operating on an eclipse-VSHFWURPHWHUDWÛ&HTXLSSHGZLWKD7+$7)*
EURDGEDQG KLJK VHQVLWLYLW\ 3XOVH )LHOG *UDGLHQW µ$XWRWXQH70¶  PP SUREH was used to 
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DQDO\VHVDPSOHV6HWWLQJVZHUHDVIROORZV0+]DWÛ&RQDQHFOLSVH-400 spectrometer. 
1D-NMR spectra were obtained using the following parameters; 16-32k data points, spectral 
width of 7199 and pulse width of 5.4750 Hz respectively, an acquisition time of 1.14 min and 
a relaxation delay of about 2.0 s.   
Prior to preparation for MS analysis, the extracts and fractions were dried under 
QLWURJHQȝl dichloromethane and 450 ȝl methanol were then added to the MS vials (only 
PHWKDQROȝl) was added to MFF1, and FEME$ȝl blank was prepared for each 
solvent mixture. Mobile phases were prepared (1l of 0.1% formic acid in distilled water and 
0.8L of 0.1% formic acid in acetonitrile) for use in MS analysis.  A hyphenated Exactive 
Dionex UltiMate 3000 HPLC system (Thermo FisheU6FLHQWLILF,QF8.VHWDWÛ&ZDVXVHG
to perform HPLC-HRMS (both positive and negative ion modes) on extracts and fractions.  A 
silica type 75.0 x 3.0 mm C18 ACE HPLC column (Hichrom Limited, UK) was employed. 
Particle size of the silica was 5 µm, pore size 100Å with a pore volume of 1.0 ml/g and a surface 
area of 300 m2/g which was maintained at a temperature of 22°C and an approximate pressure 
of 37 bar. The column was eluted with a linear gradient of 90% A (0.1% v/v formic acid in 
water) and 10% B (0.1% v/v formic acid in acetonitrile) mobile phases with a flow rate of 0.3 
ml/min over 0-35 min then to 100% B for a further 5-min isocratic elution, and a return to 
starting conditions at 40 min for re-equilibration for the last 5 min, using up a total of 45 min 
for the run. A 10 µl injection volume was used and the mass spectrometer was operated with 
UV detection at 254 nm. Approximately 1 mg of the extracts was dissolved in 1 ml HPLC 
grade methanol and solutions containing insoluble materials were filtered to avert blockade of 
the sample introduction line. The samples were transferred to 1.5 ml glass HPLC auto sampler 
vials from which the Agilent 1100 auto sampler withdrew samples that were set at 200 µl/min 
ejection speeds, one wash cycle and 20 wash strokes. 
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MS data were processed and analysed using MZMine and Dictionary of Natural 
Products while the 1H-NMR spectra were processed and analysed using MNova v.8.0 software. 
 
 
2.6 Statistical Analysis 
All data were expressed as mean ± standard error of mean (SEM). Concentration-response 
curves were produced using GraphPad Prism v. 6.0 (SanDiego, CA) for each extract. IC50 
values were calculated using the equation: Response = (Bottom + (Rmax ± Bottom))/(1 + 10(Log 
IC50 ± Log concentration)). 
 
3. Results 
3.1 Cell Inhibition Profile of Extracts and FEBH 
It was observed that all extracts tested exhibited greater than 80% cell growth inhibition, except 
for MFF1 which displayed cell growth enhancement (Fig. 1).  Results of this cell growth 
inhibition assay assisted in selection of extracts for further study. 
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Figure 1: Mean % A2780 cell inhibition after incubation with all crude Ficus exasperata 
extracts (figs, stem bark and leaves) at a concentration of 1 mg/mL for 24 h. Compared to 
control, mean % inhibition ranged from -92.5% to 100.7%. Experiments were completed in 
quadruplicate and results displayed as mean ± standard error mean (some error bars too small 
to be seen). (extracts n=4, controls n=8). 
 
3.2 Cell Inhibition Profile of FEBE Fractions 
It was observed that all fractions exhibited good inhibitory activity at higher concentrations of 
DQGȝJPl (Fig. 3A-D). Curve-fitting allowed for IC50 value calculation for each of the 
fractions and enabled IRUFRPSDULVRQRIHDFKIUDFWLRQ¶VDFWLYLW\ 
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Log IC50 YDOXHVUDQJHGEHWZHHQȝJP/DQGȝJP/ (Fig. 4).  There were 
no statistically significant differences between the log IC50 values of all FB1 fractions; an 
indication that each fraction possesses equipotent effects on A2780 cell growth.  
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Figure 3(A-D): Concentration-Response curves for FB1 fractions. Inoculation (24 h) with 
extract concentrations ranging from 1-100 µg/mL resulted in % A2780 cell inhibition values 
ranging -27.1% to 100.9% (compared to control). EC50 values between 15.2 and 34.51 µg/ml.  
Experiments were completed in quadruplicate and results displayed as mean ± standard error 
mean (n=32). 
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Figure 4: Comparison of log IC50 values for each of the FEBE1 fractions. Experiments 
completed in quadruplicate with results displayed as mean ± standard error mean (n = 32). One-
way ANOVA with Tukey's multiple comparison test yielded no significant differences between 
the log IC50 values of any of the fractions (p = 1.00, significance at p<0.05).
Peer-reviewed accepted author manuscript for the following research output: Bafor, E. E., McKenna, J., Rowan, E. G., & Edrada-Ebel, R. 
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3.3 Cell Inhibition Profile of Partitioned H1 
Inhibitory effects of H1-HEX and H1-MET were also analysed at a single concentration of 
ȝJPl. It was observed during the screening stage that both H1 fractions exerted significant 
inhibitory effects on A2780 cells (Fig. 5). The results were similar to those of the FB1 fractions 
DWȝJP/Fig. 3).  
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Figure 5: Mean % A2780 cell inhibition exhibited after incubation with 100 mg/mL H1-HEX 
and H1-MET extracts for 24 h. Mean % cell inhibition values of 97.2% and 97.9% were 
obtained for H1-HEX and H1-MET respectively, compared to control. Inhibition values 
attributed to 1% DMSO and 100% DMSO were 1.6 % and 99.1% respectively. Experiments 
were completed in octuplicate and results displayed as mean ± standard error mean (some error 
bars too small to be seen). (n=8) 
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3.4 Cell Morphology Examination 
Microscopic examination of cells was also carried before and after inoculation of the A2780 
cells with FE fractions. Visual comparisons allowed for crude detection of morphological 
changes as well as changes in cell density. On the most part, visual findings were congruent 
with bio-assay data. Reductions in cell numbers, cell lysis and clumping of cells after addition 
of the active samples were observed (Fig. 6). 
  
A1            A2 
 
B1            B2 
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C1            C2 
Figure 6: Images of A2780 cells (passage #40 and x10 magnification) using Moticam 800 x 
600 pixels with Nikon TMS microscope, before (left) and after inoculation and incubation 
(right). A1 and A2 represent cells before and after inoculation with FB1-16, B1 and B2 before 
and after inoculation with 100% DMSO and C1 and C2 are controls (before and after 24 h 
LQFXEDWLRQ6FDOHEDUVGHQRWHȝP.  
 
3.5 Identification of Chemical Constituents 
Preliminary identification of the active FB1 fractions was performed utilizing both MS and 
NMR analyses. Focusing on the two most active fraction, fraction FB1-12 was the most potent 
cytotoxic fraction among the 18 FB1 fractions investigated with the Log IC50 value at 1.18 ± 
0.15. Structural characterization of this fraction revealed the presence of two major compounds, 
bergapten and a fatty acid. Bergapten EI-MS: m/z 217.0499 [M+, C12H8O3] (Fig. 7). 1H-NMR 
(CDCl30+]į+-G- +]į+-G- +]į+-Vį
(H-G- +]į+-G- +]įVLQJOHW-OCH3). The second compound 
was identified as oxo (5:1/5:0/8:0)] (1S, 2S)-3-oxo-2-(2'Z-pentenyl)-cyclopentaneoctanoic 
acid EI-MS: m/z 295.2276 [M+1 C18H30O3] (Fig. 7). 1H-NMR (CDCl30+]į4.12 (H-, 
m); į2.33 (H-, t, J=7.55 Hz), į2.08 (H-, d, J= 10.52), į1.32, s), į0.87, t, J= 5.90). A minor 
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compound was additionally identified via MS and Mzmine as 3beta-Hydroxy-4beta-methyl-
5alpha-cholest-7-ene-4alpha-carboxylate EI-MS: m/z 445.3678 [M+1 C29H48O3] (Fig. 7). 
The next potent fraction was FB1-10 with Log IC50 values at 1.207 ± 0.17 (Fig. 4). Structural 
characterization of FB1-10 revealed the presence of two major compounds, Jasmonic acid and 
[18:4]6z,9z,12z,15z octadecatetraenoic acid. The EI-MS of Jasmonic acid showed an m/z at 
211.133 [M+ C12H18O3] (Fig. 8). 1H-NMR (CDCl3, 400 MHz): į5.48- 5.24 (m, 2H, H-10 and 
H-9), į2.80 (dd, J = 8.08 and 13.77 Hz, 1H, H-4), į2.42-2.29 (m, 5H, H-8, H-6 and H-Į
į2.05 (dd, J = 10.20 and 9.0 Hz, 2H, H-11), į1.84 (m, 1H, H-2), į1.65 (ddd, J = 7.32; 7.91 and 
14.66 Hz, 1H, H-ȕį0.90 (m, H-12). The EI-MS of octadecatetraenoic acid showed an m/z 
at 293.2118 [M+ C12H28O3] (Fig. 8)  and the 1H-NMR spectra corresponds to identification in 
the literature [14]. 
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Figure 7. Positive HRESI-MS chromatograms showing the intensity (y-axis) and the m/z (x-
axis) of FB1-12. (A) Bergapten, (B) Cyclopentaneoctanoic acid, (C) Hydroxycholestaene 
carboxylate. 
20 
 
 
Figure 8. Positive HRESI-MS chromatograms showing the intensity (y-axis) and the m/z (x-
axis) of FB1-10. (A) Jasmonic acid, (B) Octadecatetraenoic acid. 
 
4. Discussion 
This study to our knowledge reports the first in vitro anticancer study of FE extracts on ovarian 
cancer cell lines. FE is the least studied Ficus species [15] but yet appears to hold potential in 
medicinal effects. Examination of the NMR spectra and MS data, collected from FB1 fractions, 
revealed the presence of fatty acids (FAs) which appear to play a role in the antiproloferative 
effects observed in this study.  The impact of FAs intake has been evaluated in terms of cancer 
21 
 
development risk and cancer treatment.  Reductions in cancer development risk have been 
observed upon long-term intake of long-chain polyunsaturated FAs (LCPUFAs) [16].  Addition 
of LCPUFAs to currently used chemotherapeutic agents resulted in improved clinical 
effectiveness and reduced non-target tissue toxicity [16].  It has been proposed that anticancer 
activity of LCPUFAs is mediated by an anti-inflammatory effect.  LCPUFAs from marine 
sources has been associated with potential risks and unpleasant side-effects [16].  Therefore, 
FE may enable production of FAs displaying anticancer effects from a non-marine source with 
potentially less or no associated risks.  One study observed no benefit after administration of 
omega-3 FAs in terms of OC risk reduction [17], whilst some FAs may possibly be associated 
with the development of resistance to cancer chemotherapy [16].  The available evidence is 
inconclusive; however, it appears to favour the possibility of some FAs possessing anticancer 
activity. In addition to the fatty acids discovered in this study was jasmonic acid which belongs 
to the family of plant stress hormones that are able to activate cellular responses (cell death 
inclusive) in response to stress conditions in plants, and can also subdue the proliferation 
process of cells or cause apoptosis in different types of cancer cells without affecting the normal 
cells [18].  Jasmonates occur universally in plants but not in animals [19, 20]. Jasmonates such 
as 12-oxo phytodienoic acid (OPDA), jasmonic acid (JA), methyl jasmonate (MeJA), 
jasmonoyl isoleucine (JA-Ile), and 12-hydroxy-jasmonic acid (12-OH-JA) are ubiquitously 
occurring signaling compounds formed in plants in response to abiotic and biotic stresses [21]. 
Linolenic acid is a precursor of Jasmonates and they are synthesized through an octadecanoid 
pathway. They can therefore be regarded as plant-derived oxylipins similar to mammalian 
oxylipins such as prostaglandins and leukotrienes with which they share structural similarities 
[22]. Prostaglandins and leukotrienes also play a role in stress conditions. Jasmonic acid and 
derivatives play a role in the regulation of plant immunity, germination, and development [21] 
as well as in plant defense against oxidative stress which may be due to injury or ozone 
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exposure [23].  Recently the anti-cancer properties of jasmonates have been intensively studied 
[18, 26±29]. plants with high content of jasmonic acid such as Viscum album are currently of 
pharmaceutical interest [30]. 
Currently used OC chemotherapeutic agents, such as cisplatin, can be compared, in 
terms of inhibitory effects, to the FB1 fractions.  Work by Kieger et al. (2010) observed an 
IC50 YDOXHRIȝ0ȝJP/IRUcisplatin using A2780 cells (under the same conditions 
used in this research) [31].  This current study observed that FB1-12 was the most potent 
fraction (IC50 YDOXHRIȝJPl).  It is very promising to note that an unrefined FE fraction 
has approximately one third of the inhibitory activity of cisplatin.  Increasing levels of 
resistance to commonly used anticancer agents make this research valuable.  It has been 
observed that treatment of cisplatin-resistant A2780 cells with cisplatin resulted in an IC50 
YDOXHRIȝ0ȝJPl) [31] displaying the severity of the situation with regards to 
resistance.  Four-fold increases in cisplatin concentration would be required for these cells; this 
is impractical due to well-known toxicity problems with cisplatin.  As such, new treatments are 
urgently required to combat resistance; this research provides the starting point for further 
research into the possible development of an anticancer agent from FE.    
FEBH2, with inactivity displayed under the studied conditions was observed to contain 
95% bergapten (data not shown), which has a very similar structure to psoralen (Chunyan et 
al., 2009).  Psoralen is known to exhibit phototoxicity (Chunyan et al., 2009), with applications 
in the treatment of skin disorders, such as psoriasis, when used in combination with UVA.  It 
would therefore, be reasonable to infer that bergapten may also exhibit photo toxicity.  
Research by two other groups displayed anti-proliferative actions of bergapten in breast cancer 
cells (Panno et al., 2012, Panno et al., 2010).  Bergapten may have applications in the treatment 
of diseases other than cancer, and future research could evaluate such effects 
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All FB1 fractions were observed to inhibit A2780 cell growth; however, there were no 
statistically significant differences between the fractions.  It may be the case that the FB1 
IUDFWLRQV¶DFWLYLW\LVGXHWRRQHVLQJOHFRPSRQHQWRUYDULDWLRQVRIDFRPSRQHQWSUHVHQWLQDOO
of the fractions to varying degrees.  Whilst no statistical significance was displayed, there is 
still the possibility that the differences in IC50 values may be of clinical significance.  
Exploration of other uses for FE extracts could also be a direction for further research.  Initial 
investigations of other uses have been carried out, with FE extracts displaying antimicrobial 
activity against certain micro-organisms (Dongfack et al., 2012).    
With regards to toxicity effects on normal dividing cells, some work has already been 
carried out in this area.  Sowemimo et al., (2007) observed a lack of toxicity when FE leaf 
extracts were tested in two animal models.  In addition, short-term extract administration was 
found to be safe, with no effects on haematological parameters, body weight or temperature 
(Bafor and Igbinuwen, 2009).   
Results observed with the MFF1 extract provides a scope for further research; with focus on 
the reasons for cell growth enhancement.  Reasons for this are yet unknown. 
 
5.4 Conclusions 
In conclusion it has been shown that the stem bark of F. exasperata contains fatty acids that 
exerts potent inhibitory effects on A2780 OC cells, in particular, The hexane extracts of the 
leaves also exhibits similar actvity.  F. exasperata therefore shows significant potential as a 
cytotoxic agent. 
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